Results 151 to 160 of about 75,992 (272)

Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis. [PDF]

Clinicoecon Outcomes Res
Li B, Yang J, Li J, Huang J, Li Z.
europepmc   +1 more source

From Tumour to Bloodstream: Advancing PD‐L1 Testing With Liquid Biopsies in Non‐Small Cell Lung Cancer

Cytopathology, EarlyView.
This review explores liquid biopsy as a complementary approach to tissue‐based PD‐L1 assessment in advanced NSCLC treated with immune checkpoint inhibitors. Focusing on circulating tumour cells, extracellular vesicles, and circulating tumour DNA, it summarises current evidence, technical challenges, and future perspectives for personalised ...
R. Leporati, V. Callegari, A. Ancora, M. Palmieri, B. Riccò, E. Cabitza, L. Trudu, K. Di Emidio, C. Chiavelli, A. Eccher, I. Mastrolia, V. Catani, S. Bettelli, G. Guaitoli, M. Dominici, F. Bertolini   +15 more
wiley   +1 more source

Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery. [PDF]

Eur Urol Open Sci
Tazawa S, Shinohara M, Kawashima Y, Sekine Y, Narita S, Kobayashi S, Abe N, Narita T, Fujita N, Mikami J, Okamoto T, Yamamoto H, Numakura K, Sato S, Habuchi T, Ohyama C, Hatakeyama S.   +16 more
europepmc   +1 more source

Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study. [PDF]

PLoS One
Huizer TJ, Strijdhorst A, Beerepoot LV, van Berge Henegouwen MI, van Doorn L, Derks S, Wijnhoven BPL, Mostert B, van Laarhoven HWM.   +8 more
europepmc   +1 more source

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Adjuvant immune checkpoint inhibitors (ICI) and targeted therapy (TT) have revolutionized treatment management for patients with melanoma. However, the current German S3 guideline does not differentiate between patients with and without adjuvant therapy in its recommendations for imaging intervals and follow‐up monitoring, leading to
Markus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling, Kai‐Martin Thoms, Frank Meiss, Markus V. Heppt, Anja Gesierich, Konstantin Drexler, Friedegund Meier, Max Schlaak, Andrea Forschner, Lisa Zimmer   +11 more
wiley   +1 more source

Indirect Comparison of the Efficacy of Pembrolizumab Versus Nivolumab as Adjuvant Options for Stage IIB/IIC Melanoma. [PDF]

Target Oncol
Andreikos DA, Argyropoulou I, Theocharopoulos C, Anastasopoulou A, Stefanou D, Lyrarakis G, Schadendorf D, Gogas H, Ziogas DC.   +8 more
europepmc   +1 more source

Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Complete lymph node dissection (CLND) is the standard of care in patients with regional nodal melanoma macrometastasis. However, evidence on surgical procedures in the era of adjuvant systemic therapies is lacking. Patients and Methods This retrospective multi‐center study included stage IIIB–D melanoma patients with ...
Kristine E. Mayer, Jessica C. Hassel, Jannik Sambale, Michael Erdmann, Mihaela‐Anca Sindrilaru, Julia Oberschmied, Alexander Thiem, Dirk Tomsitz, Jana Knuever, Max Schlaak, Carola Berking, Christian Posch, Tilo Biedermann, Oana‐Diana Persa   +13 more
wiley   +1 more source

Checkpoint inhibitors in microsatellite instability-high metastatic colorectal cancer: treatment strategies, specificities, and care management questions. [PDF]

ESMO Gastrointest Oncol
André T, Lonardi S, Zaanan A, Cohen R, Taieb J.   +4 more
europepmc   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source

Metastatic Tumour Burden as Prognostic Factor in Nivolumab-Treated Metastatic Renal Cell Carcinoma: An Exploratory Study. [PDF]

Curr Oncol
Uccello M, Gee AL, Bennett JA, Hazell HL, Ruiz-Echarri Rueda M, Beresford MJ.   +5 more
europepmc   +1 more source